BR9612359A - Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos - Google Patents

Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos

Info

Publication number
BR9612359A
BR9612359A BR9612359A BR9612359A BR9612359A BR 9612359 A BR9612359 A BR 9612359A BR 9612359 A BR9612359 A BR 9612359A BR 9612359 A BR9612359 A BR 9612359A BR 9612359 A BR9612359 A BR 9612359A
Authority
BR
Brazil
Prior art keywords
protein
nucleic acid
host cell
chimeric polypeptide
associated methods
Prior art date
Application number
BR9612359A
Other languages
English (en)
Portuguese (pt)
Inventor
Sauvage Frederic J De
Nancy Levine
Richard L Vandlen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9612359A publication Critical patent/BR9612359A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR9612359A 1995-12-27 1996-12-19 Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos BR9612359A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57949495A 1995-12-27 1995-12-27
US66718496A 1996-06-20 1996-06-20
PCT/US1996/020718 WO1997024440A1 (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life

Publications (1)

Publication Number Publication Date
BR9612359A true BR9612359A (pt) 1999-07-13

Family

ID=27077779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9612359A BR9612359A (pt) 1995-12-27 1996-12-19 Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos

Country Status (14)

Country Link
EP (1) EP0870026B1 (enExample)
JP (1) JP4037905B2 (enExample)
CN (1) CN1154726C (enExample)
AT (1) ATE267255T1 (enExample)
AU (1) AU1520097A (enExample)
BR (1) BR9612359A (enExample)
CA (1) CA2238307A1 (enExample)
CZ (1) CZ9802013A3 (enExample)
DE (1) DE69632546T2 (enExample)
IL (1) IL124831A0 (enExample)
MX (1) MX9804687A (enExample)
NZ (1) NZ326592A (enExample)
RU (1) RU2178307C2 (enExample)
WO (1) WO1997024440A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
EP1835030A1 (en) * 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
IL132380A0 (en) * 1997-04-17 2001-03-19 Amgen Inc Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
JP4380067B2 (ja) 1998-04-23 2009-12-09 味の素株式会社 抗血栓活性物質及びグリコカリシンの検出法
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
AU2002252035A1 (en) * 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
BRPI0406605B8 (pt) * 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
CN104147596A (zh) * 2013-05-14 2014-11-19 李荣秀 生物药非共价结合聚合物延长治疗浓度的方法及用途
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
WO1997024440A1 (en) 1997-07-10
JP2000504210A (ja) 2000-04-11
EP0870026A1 (en) 1998-10-14
CA2238307A1 (en) 1997-07-10
JP4037905B2 (ja) 2008-01-23
CN1205738A (zh) 1999-01-20
DE69632546T2 (de) 2005-06-30
ATE267255T1 (de) 2004-06-15
RU2178307C2 (ru) 2002-01-20
NZ326592A (en) 2001-05-25
EP0870026B1 (en) 2004-05-19
CN1154726C (zh) 2004-06-23
DE69632546D1 (de) 2004-06-24
IL124831A0 (en) 1999-01-26
CZ9802013A3 (cs) 1998-09-16
MX9804687A (es) 1998-10-31
AU1520097A (en) 1997-07-28

Similar Documents

Publication Publication Date Title
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
Kubota et al. The eighth Cct gene, Cctq, encoding the theta subunit of the cytosolic chaperonin containing TCP-1
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
KR890012000A (ko) 인간 b세포 자극인자-2에 대한 수용체 단백질
EP1798239A3 (en) G-protein coupled receptors and uses therefor
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
BRPI0411132A (pt) protéina de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, métodos para tratar um paciente com diabete melito independente de insulina e para induzir perda de peso em um paciente acima do peso, e, uso de proteìna de fusão heteróloga
BR9913360B1 (pt) proteÍna de uricase recombinante quimÉrica, molÉcula de Ácido nuclÉico isolada e purificada, vetor e cÉlula hospedeira transformada.
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
DE68928137D1 (de) Dopamin-rezeptoren und gene
IL123189A0 (en) Colon cell and colon cancer cell associated nucleic acid molecules protein and peptides
DE69933550D1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
EP1009752A4 (en) NOVEL TANGO-77 PROTEIN FAMILY MOLECULES AND USES THEREOF
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
DE69837085D1 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DK0724637T3 (da) Kortikotropinfrigørende faktor2-receptorer
Adlersberg et al. Repetitive hinge region sequences in human IgG3: isolation of an 11,000-dalton fragment.
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
Hasegawa et al. Determination of the binding site on the extracellular domain of guanylyl cyclase C to heat-stable enterotoxin
LV10491A (lv) SAF polipeptids gens promoters un to pielietojums ekspresijai STREPTOMYCES sunas
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
Nakamura et al. Tailored synthesis of 162‐residue S‐monoglycosylated GM2‐activator protein (GM2AP) analogues that allows facile access to a protein library
ATE229074T1 (de) Rekombinante chladosporium herbarum allergene
ATE132192T1 (de) Rekombinantes produkt

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.